<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Fri, 25 Sep 2026 16:49:23 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] 子宮収縮を抑制して早産予防を担いうる米国承認薬が幾つか見つかった</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110739&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110739&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 16:49:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110739&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Kyverna社の自己免疫疾患治療CAR-T・miv-celの効果が1年経っても衰えず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110738&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110738&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 16:21:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110738&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] RocheがAtavistik社と協力して心血管腎臓代謝疾患治療アロステリック薬を作る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110737&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110737&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 15:22:22 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110737&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyの週1回皮下注射インスリンOnswik/オンスウィクを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110736&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110736&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 14:49:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110736&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ファージの逆転写酵素遺伝子近くのCRISPR似の反復配列をAnthropicのAIが発見</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110735&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110735&amp;ref=rss</guid>
		<category>技術 / 情報技術（IT） / 全般 || 技術 / ゲノム（遺伝子） / 全般</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 14:02:58 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110735&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AIが誂えた胃癌薬のPh1試験を始めたBigHat社が7500万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110734&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110734&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 12:43:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110734&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyが中国のInnoCare Pharmaと組んで新薬を開発する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110733&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110733&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 12:08:46 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110733&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] MerckのWnt薬remigromigの糖尿病黄斑浮腫治療がRocheのLucentisに劣らず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110732&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110732&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 11:56:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110732&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] RocheがEarendil LabsのAI頼みの癌治療二重特異性抗体作りに取り組む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110731&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110731&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 11:25:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110731&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 先立つ治療3回以上の3種抵抗性骨髄腫患者全員にGileadの抗BCMA CAR-Tが奏効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110730&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110730&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 09:55:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110730&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] うつ病治療BDNF伝達増幅薬のPh1試験までの資金3000万ユーロをKasvu社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110729&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110729&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 08:50:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110729&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Acadia社の5HT2A受容体抑制薬がアルツハイマー病精神症状への有意効果なし</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110728&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110728&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 08:19:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110728&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 小細胞肺癌にシスプラチンが付け入れなくする小ぶりな蛋白質SCRMPを新発見</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110727&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110727&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 25 Sep 2026 07:15:42 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110727&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Vertex社のAPOL1阻害薬inaxaplinがAPOL1絡み腎疾患相手のPh2b試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110726&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110726&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 24 Sep 2026 16:27:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110726&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Caliway社の脂肪細胞死誘導薬CBL-514注射で脂肪腫患者の痛みが有意に緩和</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110725&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110725&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 24 Sep 2026 14:49:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110725&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rocheの補体B因子抑制薬sefaxersenがIgA腎症Ph3試験で蛋白尿低下目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110724&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110724&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 24 Sep 2026 13:01:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110724&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] batoclimabに代わるImmunovant社の後進FcRn阻害薬IMVT-1402のPh2試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110723&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110723&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 24 Sep 2026 12:12:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110723&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Elevar社の胆管癌薬Lyrfigtu/リルフィグツを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110722&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110722&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 24 Sep 2026 10:01:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110722&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Enveda社が臨床試験進行中の3つの経口薬の開発資金3億1100万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110721&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110721&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 24 Sep 2026 08:02:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110721&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] HIV小児の8週間毎Cabenuva注射への切り替えがより有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110720&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110720&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 16:38:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110720&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Boomrayの前臨床段階の秘密の放射性薬をNovartisが手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110719&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110719&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 15:44:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110719&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Celldex社の抗KIT抗体barzolvolimabの慢性特発性蕁麻疹Ph3試験が目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110718&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110718&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 15:27:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110718&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] RNAスプライシングに付け入る癌治療をBoehringerがEnvisagenicsと組んで作る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110717&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110717&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 14:26:46 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110717&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 大塚製薬のFUS抑制薬ulefnersenのFUS変異筋萎縮性側索硬化症Ph3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110716&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110716&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 11:29:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110716&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Amgenの抗CD40L薬が中等〜重度全身病状のシェーグレン症候群Ph3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110715&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110715&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 08:48:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110715&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Cue社の抗IgE抗体がXolairより見栄えする蕁麻疹治療効果を中国Ph2試験で示した</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110714&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110714&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 23 Sep 2026 07:55:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110714&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 肥えた2型糖尿病患者の体重がRocheのGLP-1/GIP受容体活性化薬で15.5%低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110713&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110713&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 16:22:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110713&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Sling社が甲状腺眼症薬linsitinibのPh3試験資金1億2300万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110712&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110712&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 13:46:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110712&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Novo社のCagriSemaが2型糖尿病Ph3試験でLillyのZepboundを凌ぐ体重低下達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110711&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110711&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 13:15:19 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110711&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 神経内分泌腫瘍を治療する放射性薬の承認を逃して間もないITM社をTelix社が買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110710&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110710&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 12:09:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110710&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Beacon社のX連鎖網膜色素変性症（XLRP）遺伝子治療の大一番Ph2/3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110709&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110709&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 11:38:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110709&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] J&amp;Jの抗精神病薬Caplytaで躁うつ病患者の躁症状改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110708&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110708&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 09:52:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110708&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Alkermesのオレキシン2受容体活性化薬がPh1b試験の成人患者ADHD症状を改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110707&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110707&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 09:31:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110707&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Lillyの乳癌薬2つInluriyoとVerzenioの組み合わせ治療を米国FDAが承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110706&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110706&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 08:14:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110706&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] NovoがAnthropicと提携して新薬開発とAI頼みのソフトウェア開発を推進する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110705&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110705&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 07:53:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110705&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 整形外科感染症の術後の抗生物質全身投与はほんの7日間で事足りそう</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110704&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110704&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 22 Sep 2026 07:18:58 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110704&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 腺腫除去後の最初の内視鏡検査を早まきで3年目にしたところで大腸癌は減らず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110703&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110703&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 16:00:46 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110703&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 妊婦がアレルゲンを多めに摂取しても赤ちゃんのそれらへのアレルギーは減らず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110702&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110702&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 15:28:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110702&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 急性リンパ性白血病と診断されたばかりの小児のBlincyto治療で無事生存が改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110701&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110701&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 13:52:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110701&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 世界で急増する非結核性抗酸菌感染の所在を4時間足らずで同定する診断技術開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110700&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110700&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 13:04:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110700&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 抗HLA-E-VL9抗体がNK細胞やT細胞による腫瘍細胞やHIV感染細胞の除去を促す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110699&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110699&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 11:46:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110699&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 肥大型心筋症の病期や遺伝配列素因ごとの遺伝子活動の特徴を把握</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110698&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110698&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 09:57:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110698&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ニューモシスチス ジロベシの変異発生をミコフェノール酸が促す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110697&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110697&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 09:41:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110697&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 韓国SK社が同郷の1ST社との取り引きで前臨床段階パーキンソン病薬を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110696&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110696&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 21 Sep 2026 07:05:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110696&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Kallyope社の新しい仕組みの肥満薬3つをNovo社が取得</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110695&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110695&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 20 Sep 2026 16:41:46 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110695&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Xenon社のKv7カリウムチャネル開口薬の神経精神疾患試験の被験者組み入れ停止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110694&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110694&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 20 Sep 2026 16:35:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110694&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 親譲りの小脳性運動失調へのIntraBio社のAqneursa使用も米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110693&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110693&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 20 Sep 2026 16:16:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110693&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 韓国Orum社からのGSPT1分解薬付き抗CD33抗体の臨床開発をBMSが中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110692&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110692&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 20 Sep 2026 15:44:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110692&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BI社のアルドステロン合成酵素阻害薬vicadrostatのPh3試験4つの1つが不振で中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110691&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110691&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験 || 開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 20 Sep 2026 14:53:22 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110691&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 先立つ治療1回以上の濾胞性リンパ腫患者の無増悪生存がRocheのLunsumioで改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110690&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110690&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 20 Sep 2026 14:08:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110690&amp;ref=rss</comments>
	</item>
</channel>
</rss>
